BioPharmaDispatch Executive

The simple truth is that any institution that implicitly or more likely explicitly accepts suffering and even death as an inevitable consequence of its decision-making framework obviously lacks legitimacy. Or, it should lack legitimacy. We should at least discuss it beyond technical inputs and processes, shouldn't we?

Patients living with chronic pain say their pain cannot be reduced to a number, as a new patient-led communication tool launched at Parliament House in Canberra seeks to transform how pain is understood and treated.

Opening in 2028, the Sydney Biomedical Accelerator will be located at the Camperdown node of Tech Central and is designed to fast-track scientific discoveries into practical health care solutions.

Central to the initiative is the introduction of ObesiD, an Australian-first resource developed to support healthcare professionals in managing medicines for patients living with obesity.

Argenx's newly approved prefilled syringe formulation allows the treatment to be administered as a quick subcutaneous injection that takes around 20 to 30 seconds.

The $1.5 billion project builds on more than $3 billion the global biopharmaceutical company has already invested in its United States operations since 2018 and is expected to create at least 300 new jobs alongside hundreds of construction roles.

Health Minister Mark Butler has again stepped in to override the direction emerging from a federal advisory committee, abandoning a planned reclassification of intravitreal eye injections after warnings the change could harm patients financially and disrupt access to essential treatment.

Had the now-scrapped changes to FoI laws been in place in recent years, it is likely that the previously unlawful arrangements for the Opiate Dependence Treatment Program and the employment workaround that led a health department official to secretly release confidential company pricing information, leading to its publication in the infamous 'Vancouver' poster, would never have been exposed.

New Zealand's Pharmac says a new multiproduct agreement with Roche is delivering benefits for patients and the health system, reducing treatment times and freeing up thousands of infusion hours across hospitals.

Island Pharmaceuticals (ASX:ILA) has entered a strategic research collaboration with the Burnet Institute to expand the development potential of its antiviral drug portfolio and target a broader range of global viral threats.

New research presented by Amplia Therapeutics (ASX:ATX) is drawing attention to a potential strategy that could improve the effectiveness of an emerging class of cancer treatments targeting KRAS mutations, one of the most widely studied drivers of solid tumours worldwide.

Lateral Pharma has secured a significant intellectual property milestone with the granting of a U.S. composition-of-matter patent for LAT9997, the company’s next-generation therapeutic candidate targeting the LanCL pathway for the treatment of neuropathic pain.